HormonalFDA ApprovedFDA Approved

PT-141

Also known as Bremelanotide, Vyleesi

An FDA-approved melanocortin receptor agonist for treating hypoactive sexual desire disorder (HSDD) in premenopausal women.

FDA Approved - HSDD in premenopausal women (June 2019)

Regulatory Pathway

Preclinical
Phase I
Phase II
Phase III
Phase IV
Approved

Dosing Protocol

Typical Dose

1.75 mg as needed

Frequency

As needed, maximum 8 doses per month

Duration

45 minutes before activity, 1-2 hours before sexual activity

Community-reported dosing. Individual results vary. Not a medical recommendation.
Typical community protocol: 1.75 mg as needed via Subcutaneous injection (autoinjector available), As needed, maximum 8 doses per month. Dose range: 0.5-2 mg per dose. Duration: 45 minutes before activity, 1-2 hours before sexual activity.

Timing & Administration

Administer via Subcutaneous injection (autoinjector available). Frequency: As needed, maximum 8 doses per month.

Mechanism of Action

Activates melanocortin receptors, particularly MC4R in the central nervous system. Unlike PDE5 inhibitors that work on blood flow, PT-141 works through the brain's sexual arousal pathways.

Research Summary

Evidence level: fda approved. Clinical status: FDA Approved - HSDD in premenopausal women (June 2019).

Side Effects & Safety

Important Warnings

  • Monitor blood pressure
  • Skin hyperpigmentation with frequent use.
Nausea (40%)
facial flushing (20%)
injection site reactions
headache
transient blood pressure increase
skin hyperpigmentation with frequent use
vomiting
fatigue

References

No references available.